MX2020009902A - Anticuerpos con especificidad dual para pd-l1 y pd-l2 humanos y metodos de uso de los mismos. - Google Patents

Anticuerpos con especificidad dual para pd-l1 y pd-l2 humanos y metodos de uso de los mismos.

Info

Publication number
MX2020009902A
MX2020009902A MX2020009902A MX2020009902A MX2020009902A MX 2020009902 A MX2020009902 A MX 2020009902A MX 2020009902 A MX2020009902 A MX 2020009902A MX 2020009902 A MX2020009902 A MX 2020009902A MX 2020009902 A MX2020009902 A MX 2020009902A
Authority
MX
Mexico
Prior art keywords
methods
human
dual specificity
use therefor
specificity antibodies
Prior art date
Application number
MX2020009902A
Other languages
English (en)
Inventor
Eric Krauland
Bianka Prinz
Michael A Curran
Ashvin R Jaiswal
Dongxing Zha
Carlo Toniatti
Nadthakarn Boland
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of MX2020009902A publication Critical patent/MX2020009902A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/065—Poxviridae, e.g. avipoxvirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente divulgación está dirigida a anticuerpos biespecíficos que se unen tanto a PD-L1 como a PD-L2 y método de uso de tales anticuerpos para tratar cánceres, tales como aquellos que expresan o sobreexpresan PD-L1 o PD-L2 o ambos.
MX2020009902A 2018-03-23 2019-03-14 Anticuerpos con especificidad dual para pd-l1 y pd-l2 humanos y metodos de uso de los mismos. MX2020009902A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862647407P 2018-03-23 2018-03-23
US201862755408P 2018-11-02 2018-11-02
PCT/US2019/022295 WO2019182867A1 (en) 2018-03-23 2019-03-14 Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor

Publications (1)

Publication Number Publication Date
MX2020009902A true MX2020009902A (es) 2020-10-14

Family

ID=67987457

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009902A MX2020009902A (es) 2018-03-23 2019-03-14 Anticuerpos con especificidad dual para pd-l1 y pd-l2 humanos y metodos de uso de los mismos.

Country Status (12)

Country Link
US (1) US20210139591A1 (es)
EP (1) EP3768723A4 (es)
JP (2) JP2021518390A (es)
KR (1) KR20200135785A (es)
CN (3) CN117186236A (es)
AU (1) AU2019239568A1 (es)
BR (1) BR112020019042A2 (es)
CA (1) CA3092687A1 (es)
IL (1) IL277211A (es)
MX (1) MX2020009902A (es)
SG (1) SG11202009258RA (es)
WO (1) WO2019182867A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4116327A1 (en) 2017-10-11 2023-01-11 Board Of Regents, The University Of Texas System Human pd-l1 antibodies and methods of use therefor
EP3768298A4 (en) 2018-03-23 2021-12-08 Board of Regents, The University of Texas System HUMAN ANTI-PD-L2 ANTIBODIES AND PROCESSES FOR USE
EP3768726A4 (en) * 2018-03-23 2021-12-22 Board of Regents, The University of Texas System DOUBLE SPECIFICITY ANTIBODIES FOR PD-L1 AND PD-L2 AND METHOD OF USING THEREOF
TW202405011A (zh) * 2022-04-01 2024-02-01 美國德州系統大學評議委員會 針對人類pd-l1及pd-l2之雙重特異性抗體及其使用方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US20030194704A1 (en) * 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
US20040131613A1 (en) * 2003-01-08 2004-07-08 Watkins Jeffry D. TNF-alpha binding molecules
MXPA05012571A (es) * 2003-05-21 2006-02-08 Medarex Inc Anticuerpos monoclonales humanos contra el antigeno protector de bacillus anthracis.
JP5576610B2 (ja) * 2006-02-20 2014-08-20 フィロジカ リミテッド ペプチド構造のライブラリーの構築およびスクリーニング方法
CL2008001071A1 (es) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
EP2496600A1 (en) * 2009-11-04 2012-09-12 Fabrus LLC Methods for affinity maturation-based antibody optimization
BR122021025338B1 (pt) * 2009-11-24 2023-03-14 Medimmune Limited Anticorpo isolado ou fragmento de ligação do mesmo contra b7-h1, composição farmacêutica e seus usos
WO2014022758A1 (en) * 2012-08-03 2014-02-06 Dana-Farber Cancer Institute, Inc. Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use
US11352413B2 (en) * 2016-05-17 2022-06-07 Albert Einstein College Of Medicine Engineered PD-1 variants
WO2017218515A1 (en) * 2016-06-14 2017-12-21 Regeneron Pharmaceuticals, Inc. Anti-c5 antibodies and uses thereof

Also Published As

Publication number Publication date
EP3768723A1 (en) 2021-01-27
CN112105644A (zh) 2020-12-18
JP2021518390A (ja) 2021-08-02
CN117186236A (zh) 2023-12-08
WO2019182867A8 (en) 2020-09-24
CN112105644B (zh) 2023-12-05
US20210139591A1 (en) 2021-05-13
WO2019182867A1 (en) 2019-09-26
JP2023113909A (ja) 2023-08-16
BR112020019042A2 (pt) 2021-01-05
CN117586412A (zh) 2024-02-23
EP3768723A4 (en) 2021-12-29
SG11202009258RA (en) 2020-10-29
CA3092687A1 (en) 2019-09-26
IL277211A (en) 2020-10-29
AU2019239568A1 (en) 2020-09-17
KR20200135785A (ko) 2020-12-03

Similar Documents

Publication Publication Date Title
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
PH12019500668A1 (en) Anti-lag-3 antibodies and compositions
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
GEP20227440B (en) Anti-ilt4 antibodies and antigen-binding fragments
PH12020552221A1 (en) Anti-pd-1 antibodies and uses thereof
MX2022002364A (es) Anticuerpos anti-pd-l1.
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
MX2020009902A (es) Anticuerpos con especificidad dual para pd-l1 y pd-l2 humanos y metodos de uso de los mismos.
PH12018501177A1 (en) Antibodies targeting fc receptor-like 5 and methods of use
TN2017000470A1 (en) Heterodimeric antibodies that bind cd3 and tumor antigens.
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
PH12020552229A1 (en) Il-11ra antibodies
GEP20197034B (en) Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
MX2016009954A (es) Anticuerpos contra el dominio extracelular de muc1-c (muc1-c/ecd).
MX2017001599A (es) Anticuerpos novedosos y sus usos.
NZ766356A (en) Anti-pd-1 antibodies
PH12021550690A1 (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
MX2021004808A (es) Anticuerpos contra la epcam, anticuerpos activables e inmunoconjugados y usos de estos.
MX2020010951A (es) Anticuerpos anti-hla-g y utilizacion de los mismos.
MX2021002690A (es) Anticuerpos anti-avb8 y composiciones y usos de los mismos.
MX2021014193A (es) Moleculas de enlace biespecificas anti-ror1/anti-cd3.
MX2020008122A (es) Anticuerpos anti-pd-1.
MX2022002682A (es) Anticuerpos anti-cd73.
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof